Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 3/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10323856 | 0.98 | CA14 (0.34) | EPHX1HSD11B1GAACA14DPP4 | |
| SCHEMBL15285331 | 0.92 | CA14 (0.36) | HSD11B1CA14DPP4L3MBTL1 | |
| SCHEMBL6485797 | 0.91 | EPHX1 (0.35) | EPHX1HSD11B1GAACA14DPP4 | |
| SCHEMBL6486782 | 0.89 | CA14 (0.35) | EPHX1HSD11B1CA14DPP4PYGL | |
| SCHEMBL27510109 | 0.88 | EPHX1 (0.39) | EPHX1HSD11B1GAADPP4 | |
| SCHEMBL6497271 | 0.87 | CA14 (0.36) | EPHX1HSD11B1CA14DPP4L3MBTL1 | |
| SCHEMBL13494079 | 0.87 | ADH1A (0.41) | EPHX1HSD11B1GAACA14L3MBTL1 | |
| SCHEMBL13641157 | 0.86 | ASGR1 (0.33) | HSD11B1CA14DPP4 | |
| SCHEMBL1238808 | 0.86 | CA14 (0.33) | HSD11B1CA14DPP4 | |
| SCHEMBL10325232 | 0.86 | ASGR1 (0.33) | HSD11B1CA14DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-2277510-B1 | Controlled release preparation | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-26 | — | — | EP | disclosed |
| EP-1602362-B1 | DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE | TAKEDA PHARMACEUTICAL (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| US-8980322-B2 | Controlled release composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| CN-104053661-A | Thienopyrimidine Inhibitors Of Atypical Protein Kinase C | CANCER REC TECH LTD | 2014-09-17 | — | — | CN | disclosed |
| US-8784885-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8784885-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-1660091-A1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1646389-A1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1644342-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060013868-A1 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1607088-A1 | CONTROLLED RELEASE COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2005-12-21 | — | — | EP | disclosed |
| EP-1602362-A1 | DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE | Takeda Pharmaceutical Company Limited (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-20050222210-A1 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-06 | — | — | US | disclosed |
| WO-2005007633-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2005007165-A1 | PYRIMIDINE-2, 4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2005007164-A1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222210-A1 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | SI, VIP, PGC | EPHX1 621/4885HSD11B1 1172/4885GAA 235/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | EPHX1 3226/4885HSD11B1 2229/4885GAA 27/4885 |
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | EPHX1 2986/4885HSD11B1 2560/4885GAA 398/4885 |
| US-20060013868-A1 | Controlled release preparation | SLC18A1, MLN, GCG | EPHX1 2986/4885HSD11B1 2560/4885GAA 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.